WO2011109262A2 - Cancer diagnosis and imaging - Google Patents
Cancer diagnosis and imaging Download PDFInfo
- Publication number
- WO2011109262A2 WO2011109262A2 PCT/US2011/026416 US2011026416W WO2011109262A2 WO 2011109262 A2 WO2011109262 A2 WO 2011109262A2 US 2011026416 W US2011026416 W US 2011026416W WO 2011109262 A2 WO2011109262 A2 WO 2011109262A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell cycle
- imaging
- cycle inhibitor
- mammal
- condition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H30/00—ICT specially adapted for the handling or processing of medical images
- G16H30/20—ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
Definitions
- the cell cycle is the series of events occurring in a cell leading to its division and duplication.
- the cycle can be divided into two periods, interphase and mitosis. Transit through these two periods of the cell cycle is known as proliferation.
- interphase the cell grows, accumulates nutrients needed for mitosis and duplicates its DNA.
- mitosis the cell splits itself into two distinct daughter cells.
- Interphase includes three distinct phases, Gap 1 (Gj) phase, S phase and Gap 2 (G 2 ) phase while mitosis includes two processes.
- Gi phase includes the cell increasing in size, biosynthetic activities of the cell increasing and the synthesis of enzymes needed for DNA replication in the subsequent step.
- S phase includes the beginning of DNA synthesis and replication of all of the chromosomes.
- G 2 phase lasts until the cell enters mitosis and includes protein synthesis including the production of microtubules for mitosis.
- Mitosis includes a process where the cell's chromosomes are divided between the two daughter cells and a cytokinesis process where the original cell's cytoplasm divides forming two distinct daughter cells.
- the cell cycle also includes a resting phase, typically referred to as Go-
- Go- The boundaries between the various phases, for example the boundary between the G ⁇ and S phase is referred to as a cell cycle checkpoint.
- the progression of the cell cycle can be inhibited, so that a particular cell stops the cycle at a point, a cellular checkpoint, before proceeding to the next phase.
- Cell cycle checkpoints are located between the different phases of the cell cycle, with two of the checkpoints being at the interface between the Gj and the S phase (Gj/S) and the interface between the G 2 and M phase.
- a cell cycle inhibitor can stop the progression of a cell from passing to the next phase, for example a cell can be inhibited at the Gj/S cell cycle checkpoint, which forces the cell to remain in the Gi phase until the inhibitor is removed.
- the length of the cell cycle is variable. This variability is due to differing periods spent in Gi of Go while the length of time from the beginning of S phase to the end of M phase is relatively constant.
- Imaging using traditional markers relies on the increased uptake of the marker because of the increased metabolic activity of the cancer cells. This increased uptake is most noticeable once the cancer cells are in the S phase as opposed to the other cell cycle stages. If the majority of cancer cells to be imaged are not in the S phase during the typically one hour time span between administration and imaging, the image result may not be representative of the actual concentration and location of cancer cells. [0007] What is desired is a treatment to arrest the cell cycle for a clinically relevant fraction of cells at the G ⁇ /S cell cycle checkpoint, so that the efficacy of imaging markers can be enhanced.
- the present invention provides a method for imaging a disease or condition in a mammal which includes the steps of: administering a therapeutically effective amount of a cell cycle inhibitor to effectively stop proliferation of eukaryotic cells at a cell cycle checkpoint between the and S phase, stopping administration of the cell cycle inhibitor for a period of time, administering a marker to the mammal and imaging the mammal.
- Figure 1 is a schematic representation of the cell cycle.
- the outer ring includes the interphase (I) and mitosis (M) stages, with the duration of mitosis in relation to the other phases being exaggerated.
- the inner ring includes the Gap 1 (G , Gap 2 (G 2 ) and synthesis (S) phases. Gap 0 (Go) or resting phase is not shown.
- Figure 2 is a graphical representation of the ability of several chemical agents to inhibit calcium influx as compared to the same chemical agent's ability to inhibit cell proliferation.
- Figure 3 is a schematic representation of the cell cycle and the influence several calcium channel blockers have on the progression of the cell cycle.
- Figure 4 is a graphical representation of data measuring the impact of mibefradil on cell cycles.
- Figure 5 is a graphical representation of data measuring the impact of mibefradil on cell cycles.
- Figure 6 is a graphical representation of data measuring uptake of an image marker after administration of mibefradil.
- Figure 7 is a graphical representation of data measuring uptake of an image marker after administration of mibefradil.
- the term "pharmaceutically acceptable carrier, vehicle or diluent” includes any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions such as an oil/water or water/oil emulsion, and various types of wetting agents.
- the term also encompasses any of the agents approved by a regulatory agency of the US Federal government or listed in the US Pharmacopeia for use in animals, including humans.
- terapéuticaally effective amount means an amount of a compound of the present invention that ameliorates, attenuates, reduces or eliminates a particular disease or condition or prevents or delays the onset of a particular disease or condition.
- mammal it is meant to refer to all mammals, including, for example, primates such as humans and monkeys. Examples of other mammals included herein are rabbits, dogs, cats, cattle, goats, sheep, mice, rats and horses. Preferably, the mammal is a female or male human.
- pre-cancerous condition refers to a growth that is not malignant but is likely to become so if not treated.
- a "pre-cancerous condition” is also known as “pre-malignant condition” by one of ordinary skill in the art.
- T type calcium channel blockers are also known as “T type calcium channel inhibitors”.
- the method for imaging a disease or condition in a mammal includes several steps. The method can be conducted for many reasons including diagnosis of a suspected disease or condition, screening for the impact of various treatments and the monitoring of the progress of treatment. Based on the images generated from the described method, a health care
- the method can be used to image various diseases or conditions, including unstable angina, hypertension, epilepsy, neuropathic pain, petit mal seizure, absence seizure, age related macular degeneration, cancer and pre-cancerous conditions. In other embodiments, the method can be used to image tumors and pre-cancerous tumors.
- a cell cycle inhibitor is first
- a cell cycle inhibitor can be administered.
- a cell cycle inhibitor causes asynchronously proliferating cancer cells in a population to accumulate at G /S as they proceed through the cell cycle because their ability to proceed to the S phase is arrested by the cell cycle inhibitor.
- the cell For a cell to move from Gi phase to S phase through the cell cycle checkpoint, the cell requires influx of extracellular calcium to trigger biochemical cascades that are necessary for the progression. Removal of calcium from the extracellular medium blocks cell cycle transit for each cell.
- each cell persists in Gj phase as long as it would in the presence of extracellular calcium, but becomes locked in place when Gi/S is reached without calcium, thereby synchronizing cells at Gi/S. Calcium influx to a cell is necessary for proliferation and transit through the cell cycle. This is further described in Example 1 below.
- the administration of the cell cycle inhibitor increases the percentage of cells at G ⁇ /S.
- administration of cell cycle inhibitor to the mammal persists for a period of time before imaging. This period of time can be between about 1 day and about 10 days, inclusively. In another embodiment, this period of time can be between about 5 days and about 7 days, inclusively. Although the upper limits of these embodiments are 10 days and 7 days, the cell cycle inhibitor can be administered for longer periods of time.
- the dosage of cell cycle inhibitor creates a concentration in a mammal's plasma of about 1 ⁇ to about 10 ⁇ .
- the cell cycle inhibitor can be administered through several routes including parenteral, intravenous, intramuscular, intraperitoneal, intrathecal, suppository, transdermal, topical, or oral. Oral administration of the cell cycle inhibitor is most preferred. An oral administration can be administered as a dosage unit, typically a pill or capsule along with a pharmaceutically acceptable carrier.
- the cell cycle inhibitor can be one or many of several cell cycle inhibitors. For example, mibefradil, efonidipine, ethosuxamide, TTL-1177 (a proprietary compound, described in reference: Gray, L.S., Perez-Reyes, E., Gomora, J.C., Haverstick, D.M., Shattock, M.,
- These cell cycle inhibitors inhibit the influx of extracellular calcium into the cell which is critical for a number of vital cellular processes.
- the calcium necessary for these processes comes from the extracellular milieu via influx through calcium channels.
- Calcium channels are grouped into several families based upon sequence analysis, biophysical characteristics and pharmacological sensitivity. Among these is the T type calcium channel family. These calcium channels have been implicated in regulation of blood pressure, cardiac rhythm and cellular proliferation. Studies also suggest that T-type calcium channels may play an important role in age related macular degeneration. At least one pharmacological agent, mibefradil, has been proven to be clinically effective because of inhibition of T channel function. Inhibitors of calcium entry are useful for treating hypertension, cardiac arrhythmia and clinically deleterious cellular proliferation.
- T type calcium channels are present in cells, cell lines and specifically cancer cell lines. Specifically, the Cav3.2 isoform of T type calcium channels has been shown to be aberrantly expressed in breast cancer tissue as compared to normal adjacent breast tissue in Japanese women, as discussed in reference Asaga, S., Ueda, M., Jinno, H., Kikuchi, K., Itano, O., D eda, T., and Kitajima, M. (2006) Anticancer Res 26, 35-42. [0031] Cell cycle inhibitors effectively stop proliferation of eukaryotic cells at cell cycle checkpoints, including G)/S, which is further explained in Examples 2-4 below.
- an imaging marker is administered that is targeted to be uptaken in the S phase of the cell cycle.
- the period between the first administration of the cell cycle inhibitor and the imaging marker allows the
- This method increases the percentage of the cells which are in the S phase, thereby increasing the uptake of imaging marker into those cells.
- an imaging marker is administered to be uptaken or absorbed by cells in the S phase.
- the specific imaging marker will be dictated by clinical experience of one skilled in the art, where different diseases are imaged with different imaging markers.
- the same dose of an imaging marker is uptaken more readily and more specifically as compared to an imaging marker when used alone.
- the increase in imaging marker being uptaken is further described in Example 5 below.
- Cancer cells can be located within the living body by administering a substance that binds to T type calcium channels or T type calcium channel accessory proteins. The location within the body of the drug can then be determined by tagging it with substances that are detectable from outside the body.
- radioactive atoms can be localized within the body by measurements taken outside of it and examples of such atoms useful for this purpose include 99mTc, 1251, 1311, 18F, 11C, 13N, 150, 3H, 68Ga, 67Ga and 16F, among others.
- imaging markers include 11C Methionine, 2-deoxy-2- ( 18 F)fluoro-D-glucose (FDG), tritiated FDG (3H-FDG) and fluoro deoxythymidines such as [18F]-3'-fluoro-3'-deoxy-L-thymidine).
- FDG 2-deoxy-2- ( 18 F)fluoro-D-glucose
- H-FDG tritiated FDG
- fluoro deoxythymidines such as [18F]-3'-fluoro-3'-deoxy-L-thymidine
- deuterium for example, can be similarly localized using Nuclear Magnetic Resonance (NMR) and various dyes, fluorescent as well as non-fluorescent, are localized using optical techniques.
- NMR Nuclear Magnetic Resonance
- one or more imaging markers may be combined and administered to the mammal prior to imaging of the mammal.
- the mammal is then imaged.
- the imaging marker can be administered at any suitable dose, for example about 100 mBq to about 600 mBq.
- the mammal can be imaged using any suitable imaging apparatus, for example an apparatus capable of gathering a magnetic resonance image (MRI), a positron emission tomogram (PET scan) or a computer tomogram (CT scan).
- MRI magnetic resonance image
- PET scan positron emission tomogram
- CT scan computer tomogram
- the images gleaned by a suitable imaging apparatus will be more sensitive than images taken of mammals with no pre-treatment of a cell cycle inhibitor.
- the scans taken after administration of cell cycle inhibitors will be more sensitive because the diseased cells will have a higher uptake of the imaging markers as compared to uptake of imaging markers of cells that have not had an administration of a cell cycle inhibitor.
- T- type calcium channel blockers are variably efficient at halting the cell cycle based on the type of tumor being targeted.
- a pancreatic cancer tumor may react differently as compared to a pancreatic tumor in response to a dosage of T-type calcium channel blockers.
- T channel calcium channel blockers mibefradil (mib), nickel (Ni) or TTL-1177 (a proprietary compound owned by the assignee Tau Therapeutics), before adding nocodazole. Absent an effect on the T channel blockers, cells would be locked at the cell cycle checkpoint between G 2 and M by nocodazole as happened with cells treated with it alone. Instead, treatment with the T type calcium channel blockers arrested cells at the cell cycle checkpoint between Go and Gi and prevented
- PC3 cells were incubated with varying concentrations of mibefradil for varying times.
- the PC3 cells were incubated with either a 5 ⁇ concentration or a 10 ⁇ concentration for either 24 hours or 48 hours.
- an increase in concentration and contact time of the mibefradil increases the proportion of cells in the Gl phase.
- the efficacy of the uptake of imaging markers after treatment with a cell cycle inhibitor was determined.
- Human colon cancer cells, cell line HT29 were first incubated for 24 hours with the cell cycle inhibitor mibefradil at concentrations of 5 ⁇ (5uM-FDG-HT29) and 10 ⁇ (10uM-FDG-HT29). After 24 hours of incubation with the mibefradil, the HT29 cells were removed from mibefradil contact. After 60 minutes of being removed from mibefradil contact, the imaging marker 2-deoxy-2-( 18 F)fluoro-D-glucose (hereinafter, "FDG”) was administered.
- FDG 2-deoxy-2-( 18 F)fluoro-D-glucose
- uptake of the imaging marker FDG into the HT29 cells increased in the cells incubated with mibefradil as compared to the cells that were not incubated.
- the increase in uptake of FDG was about 100% as compared to uptake of cells not incubated with mibefradil.
- the uptake of an imaging marker was also determined in human lung cancer cells of cell line A549.
- A549 cells were incubated with 5 ⁇ , 10 ⁇ and 15 ⁇ concentrations of the cell cycle inhibitor mibefradil for 24 hours. After 24 hours of incubation with the mibefradil, the A549 cells were removed from mibefradil contact. After 30 minutes of being removed from mibefradil contact, the imaging marker tritiated FDG (hereinafter "3H-FDG”) was administered. As can be seen from FIG. 7, uptake of the 3H-FDG was maximal at 5 ⁇ , with an increase in uptake being observed at all concentrations of mibefradil incubation. Although not shown, incubation of human prostate cancer cells of the PC3 cell line with 10 ⁇ mibefradil for 72 hours increased uptake of the subsequently introduced imaging marker 3H-FDG by about 60%.
- a mammal in this embodiment the mammal is a human, is chosen to be imaged. This choice can be made based on various factors including past treatment for a disease, in this embodiment prostate cancer, or as a possible confirmation of a diagnosis.
- the human initially receives an administration of a cell cycle inhibitor in a therapeutically effective amount, in this embodiment an oral pill delivering a dosage of mibefradil twice daily for 6 days prior to a scheduled imaging session. After the 6 days of dosages are administered, the administration of mibefradil is ceased.
- FDG an imaging marker
- 6 hours pass between ceasing administration of the mibefradil and administration of an imaging marker, which in this example is FDG.
- FDG is injected into the human at a sufficient dosage.
- the human is then imaged with a PET scan.
- the data produced from the PET scan is more precise and more accurate than data available from PET scans wherein the patient did not receive a cell cycle inhibitor.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Primary Health Care (AREA)
- Radiology & Medical Imaging (AREA)
- Medical Informatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012556123A JP6017964B2 (en) | 2010-03-01 | 2011-02-28 | Cancer diagnosis and imaging |
ES11751125.3T ES2557407T3 (en) | 2010-03-01 | 2011-02-28 | Imaging procedure of a disease |
AU2011223883A AU2011223883B2 (en) | 2010-03-01 | 2011-02-28 | Cancer diagnosis and imaging |
CN201180011495.2A CN102781316B (en) | 2010-03-01 | 2011-02-28 | Cancer diagnosis and imaging |
US13/581,390 US9427429B2 (en) | 2010-03-01 | 2011-02-28 | Cancer diagnosis and imaging |
SG2012055232A SG183114A1 (en) | 2010-03-01 | 2011-02-28 | Cancer diagnosis and imaging |
EP11751125.3A EP2542155B1 (en) | 2010-03-01 | 2011-02-28 | Method for imaging a disease |
MX2012010119A MX360640B (en) | 2010-03-01 | 2011-02-28 | Cancer diagnosis and imaging. |
KR1020127022975A KR101821343B1 (en) | 2010-03-01 | 2011-02-28 | Cancer diagnosis and imaging |
CA2787673A CA2787673A1 (en) | 2010-03-01 | 2011-02-28 | Cancer diagnosis and imaging |
ZA2012/05377A ZA201205377B (en) | 2010-03-01 | 2012-07-18 | Cancer diagnosis and imaging |
IL221035A IL221035A0 (en) | 2010-03-01 | 2012-07-19 | Cancer diagnosis and imaging |
HK13106393.5A HK1179143A1 (en) | 2010-03-01 | 2013-05-30 | Method for imaging a disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30903010P | 2010-03-01 | 2010-03-01 | |
US61/309,030 | 2010-03-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011109262A2 true WO2011109262A2 (en) | 2011-09-09 |
WO2011109262A3 WO2011109262A3 (en) | 2011-11-17 |
Family
ID=44542787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/026416 WO2011109262A2 (en) | 2010-03-01 | 2011-02-28 | Cancer diagnosis and imaging |
Country Status (14)
Country | Link |
---|---|
US (1) | US9427429B2 (en) |
EP (1) | EP2542155B1 (en) |
JP (1) | JP6017964B2 (en) |
KR (1) | KR101821343B1 (en) |
CN (1) | CN102781316B (en) |
AU (1) | AU2011223883B2 (en) |
CA (1) | CA2787673A1 (en) |
ES (1) | ES2557407T3 (en) |
HK (1) | HK1179143A1 (en) |
IL (1) | IL221035A0 (en) |
MX (1) | MX360640B (en) |
SG (2) | SG10201501496TA (en) |
WO (1) | WO2011109262A2 (en) |
ZA (1) | ZA201205377B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9427429B2 (en) | 2010-03-01 | 2016-08-30 | Tau Therapeutics Llc | Cancer diagnosis and imaging |
US11130750B2 (en) | 2017-02-15 | 2021-09-28 | Cavion, Inc. | Calcium channel inhibitors |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2576191C (en) * | 2004-08-20 | 2013-03-19 | University Of Virginia Patent Foundation | T type calcium channel inhibitors |
SG11201900336YA (en) * | 2016-07-19 | 2019-02-27 | Bristol Myers Squibb Co | Radioligands for imaging the ido1 enzyme |
UY37341A (en) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | FORMULATIONS OF GAMMA-MODIFIED RELEASE HYDROXIBUTIRATE WITH IMPROVED PHARMACOCINETICS |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
JP2022522270A (en) | 2019-03-01 | 2022-04-15 | フラメル アイルランド リミテッド | Gamma-hydroxybutyrate composition with improved pharmacokinetics in dietary intake |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002092127A1 (en) | 2001-05-11 | 2002-11-21 | Board Of Regents, The University Of Texas System | Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26 |
WO2008018642A2 (en) | 2006-08-10 | 2008-02-14 | Oncotherapy Science, Inc. | Genes and polypeptides relating to breast cancers |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1219609A (en) | 1968-07-19 | 1971-01-20 | Koninklijke Pharma Fab Nv | Diphenylmethoxyethylamino derivatives |
US3732247A (en) | 1970-08-14 | 1973-05-08 | Robins Co Inc A H | 3-di-substituted methylene pyrrolidines wherein the 1-or n-lower-alkyl substituent contains at least two carbon atoms |
US4091103A (en) | 1976-06-23 | 1978-05-23 | Ciba-Geigy Corporation | Quinolyl or isoquinolyl-lower-alkoxy-phenylene-amino derivatives |
JPS59161392A (en) | 1983-03-04 | 1984-09-12 | Nippon Shinyaku Co Ltd | Dihydropyridine derivative and its preparation |
US4906646A (en) | 1983-03-31 | 1990-03-06 | Board Of Governors Of Wayne State University | Method and composition for the treatment of tumors by administering a platinum coordination compound and a calcium channel blocker compound of the dihydropyridine class |
US4885284A (en) | 1986-01-22 | 1989-12-05 | Nissan Chemical Industries Ltd. | Dihydropyridine-5-phosphonic acid cyclic propylene ester |
FR2601366B1 (en) | 1986-07-10 | 1988-11-25 | Andre Buzas | BENZHYDRYLOXYETHYL-PIPERAZINE DERIVATIVES, PROCESSES FOR OBTAINING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME. |
JP2850376B2 (en) | 1988-08-02 | 1999-01-27 | 日産化学工業株式会社 | Anticancer drug efficacy enhancer |
DE68924456T2 (en) | 1988-08-02 | 1996-05-30 | Nissan Chemical Ind Ltd | Agents for improving drug effects for anti-tumor agents. |
FR2636946B1 (en) | 1988-09-23 | 1990-11-02 | Lipha | ((DIARYLMETHOXY) ALCOYL) -1 PYRROLIDINES AND PIPERIDINES, METHODS OF PREPARATION AND MEDICAMENTS CONTAINING THEM |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
ES2087997T3 (en) | 1990-01-12 | 1996-08-01 | Cell Genesys Inc | GENERATION OF XENOGENIC ANTIBODIES. |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP0467435A3 (en) | 1990-07-19 | 1992-04-01 | Akzo N.V. | Benzhydryl derivatives having calmodulin inhibitor properties |
GB9020051D0 (en) | 1990-09-13 | 1990-10-24 | Pfizer Ltd | Muscarinic receptor antagonists |
US5919816A (en) | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
US6413967B1 (en) | 1995-03-30 | 2002-07-02 | The University Of Virginia Patents Foundation | Inhibition of novel calcium entry pathway in electrically non-excitable cells acting as an anti-proliferative therapy |
JPH11514348A (en) | 1995-09-08 | 1999-12-07 | ベス イスラエル ディーコネス メディカル センター | Isolation of microdomains of caveole and GPI anchor proteins |
EP0853615B1 (en) | 1995-09-15 | 2003-12-10 | Neurosearch A/S | Piperidine compounds as calcium channel blockers |
TR199801581T2 (en) | 1996-02-14 | 1998-10-21 | Isis Pharmaceuticals, Inc. | �ekerle de�i�tirilmi� bo�luklu oligon�kleotid’ler. |
CA2204082A1 (en) | 1996-05-03 | 1997-11-03 | Michael William John Urquhart | Pharmaceutical compounds |
US6191156B1 (en) | 1997-04-11 | 2001-02-20 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating bladder dysfunction |
US6703374B1 (en) * | 1997-10-30 | 2004-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleosides for imaging and treatment applications |
DE69836229T2 (en) | 1997-12-03 | 2007-08-23 | Merck & Co., Inc. | COMPOSITIONS OF LOW-VOLUME-ACTIVATED CALCIUM CHANNELS AND METHOD |
CA2312477A1 (en) | 1997-12-05 | 1999-06-17 | Loyola University Of Chicago | T-type voltage-gated calcium channels and method of using same |
US6372719B1 (en) | 1998-03-04 | 2002-04-16 | Jay Cunningham | ανβ3 integrin antagonists in combination with chemotherapeutic agents |
JPH11246417A (en) | 1998-03-04 | 1999-09-14 | Nissan Chem Ind Ltd | Pharmaceutical composition for treating diabetic nephropathy |
WO2000015845A1 (en) | 1998-08-26 | 2000-03-23 | South Alabama Medical Science Foundation | T-type calcium channel |
US6251886B1 (en) | 1998-12-07 | 2001-06-26 | Schering Corporation | Methods of using temozolomide in the treatment of cancers |
EP1165508B1 (en) | 1999-04-07 | 2004-06-23 | The University of Virginia Patent Foundation | Anticancer calcium channel blockers |
US6946475B1 (en) | 1999-04-07 | 2005-09-20 | University Of Virginia Patent Foundation | Anticancer calcium channel blockers |
US7195783B2 (en) | 1999-07-09 | 2007-03-27 | Fx Life Sciences International Gmbh | Hypericin and hypericum extract: specific T-type calcium channel blocker, and their use as T-type calcium channel targeted therapeutics |
AU2001235363A1 (en) | 2000-02-25 | 2001-09-03 | Novo-Nordisk A/S | Mibefradil analogues and their use |
GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
EP1303305B1 (en) | 2000-07-27 | 2007-03-21 | Pharmacia Corporation | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure |
ZA200305980B (en) | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
CA2454637A1 (en) | 2001-07-23 | 2003-02-20 | Epidauros Biotechnologie Ag | Use of irinotecan for improved treatment of cancer based on mdr1 |
CA2469685C (en) | 2002-01-17 | 2013-03-12 | The University Of British Columbia | Bispecific antisense oligonucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
EP1506032A1 (en) | 2002-05-20 | 2005-02-16 | Research Development Foundation | Aerosol drug inhibition of lung metastases |
GB0211578D0 (en) * | 2002-05-21 | 2002-06-26 | Univ Belfast | Medicaments |
DE10227511A1 (en) | 2002-06-19 | 2004-01-08 | Max-Delbrück-Centrum für Molekulare Medizin | Medicines for acute and chronic pain |
US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
AU2003272539A1 (en) * | 2002-09-17 | 2004-04-08 | New York University | Methods of treating age associated memory impairment (aami), mild cognitive impairment (mci), and dementias with cell cycle inhibitors |
EP1609504A4 (en) | 2003-03-28 | 2010-07-21 | Nissan Chemical Ind Ltd | T-type calcium channel blockers |
TW200528107A (en) | 2003-11-25 | 2005-09-01 | Nissan Chemical Ind Ltd | T-type calcium channel inhibitor |
AU2011203315B8 (en) | 2004-02-11 | 2012-02-16 | University Of Virginia Patent Foundation | Inhibiting CAV3 isoforms and the delta25B splice varients for the diagnosis and treatment of cancer |
AU2005211764B2 (en) | 2004-02-11 | 2011-07-21 | University Of Virginia Patent Foundation | Inhibiting CAV3 isoforms and the delta25B splice varients for the diagnosis and treatment of cancer |
CA2555208A1 (en) | 2004-02-18 | 2005-09-01 | Merck & Co., Inc. | Nucleic acid molecules encoding novel murine low-voltage activated calcium channel proteins, designated-alpha 1h, encoded proteins and methods of use thereof |
US20060003020A1 (en) | 2004-03-11 | 2006-01-05 | The Regents Of The University Of Michigan | Anti-metastatic ability of mibefradil and gadolinium |
TW200538149A (en) | 2004-05-20 | 2005-12-01 | Telik Inc | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound |
WO2006003020A1 (en) | 2004-07-02 | 2006-01-12 | L'oreal | Compositions containing a triazine derivative, an arylalkyl benzoate derivative and a eutectic n-butylphthalimide/isopropylphthalimide mixture; cosmetic uses thereof |
US20120264804A1 (en) | 2004-08-20 | 2012-10-18 | University Of Virginia Patent Foundation | T type calcium channel blockers and the treatment of diseases |
EP1778245A4 (en) | 2004-08-20 | 2010-03-03 | Univ Virginia | T type calcium channel blockers and the treatment of diseases |
CA2576191C (en) | 2004-08-20 | 2013-03-19 | University Of Virginia Patent Foundation | T type calcium channel inhibitors |
US20100222406A1 (en) | 2007-09-11 | 2010-09-02 | University Of Virginia Patent Foundation | T Type Calcium Channel Blockers and the Treatment of Diseases |
US7851431B2 (en) | 2005-07-27 | 2010-12-14 | Prescription Dispensing Laboratories | Treatment of actinic keratoses with calcium channel blockers |
KR100743255B1 (en) | 2006-05-04 | 2007-07-27 | 한국과학기술연구원 | Novel 1,3-dioxoisoindole derivatives having selective antagonism of t-type calcium channel |
CN101528768A (en) * | 2006-08-10 | 2009-09-09 | 肿瘤疗法科学股份有限公司 | Genes and polypeptides relating to breast cancers |
NZ578472A (en) | 2006-12-19 | 2012-06-29 | Genentech Inc | Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
WO2008137107A1 (en) | 2007-05-02 | 2008-11-13 | Krouse Andrew J | Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions |
WO2008141189A1 (en) | 2007-05-09 | 2008-11-20 | Elixir Pharmaceuticals, Inc. | Ghrelin modulating compounds and combinations thereof |
US8877803B2 (en) | 2007-09-10 | 2014-11-04 | Boston Biomedical, Inc. | Stat3 pathway inhibitors and cancer stem cell inhibitors |
JP5029328B2 (en) | 2007-12-05 | 2012-09-19 | マツダ株式会社 | Front body structure of automobile |
CA2722992A1 (en) | 2008-05-05 | 2009-11-12 | Schering Corporation | Sequential administration of chemotherapeutic agents for treatment of cancer |
RS53750B1 (en) | 2008-07-08 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Notch1 receptor binding agents and methods of use thereof |
DK2437749T3 (en) | 2009-06-05 | 2018-01-29 | Cavion Inc | COMBINED PROCEDURE FOR TREATING CANCER OR A PRECAUTION STATE |
CN102781316B (en) | 2010-03-01 | 2016-07-06 | 陶制药有限责任公司 | Cancer diagnosis and imaging |
US20130064814A1 (en) | 2011-09-12 | 2013-03-14 | Lloyd S. Gray | Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells |
-
2011
- 2011-02-28 CN CN201180011495.2A patent/CN102781316B/en not_active Expired - Fee Related
- 2011-02-28 SG SG10201501496TA patent/SG10201501496TA/en unknown
- 2011-02-28 KR KR1020127022975A patent/KR101821343B1/en active IP Right Grant
- 2011-02-28 SG SG2012055232A patent/SG183114A1/en unknown
- 2011-02-28 JP JP2012556123A patent/JP6017964B2/en not_active Expired - Fee Related
- 2011-02-28 WO PCT/US2011/026416 patent/WO2011109262A2/en active Application Filing
- 2011-02-28 AU AU2011223883A patent/AU2011223883B2/en not_active Ceased
- 2011-02-28 US US13/581,390 patent/US9427429B2/en not_active Expired - Fee Related
- 2011-02-28 MX MX2012010119A patent/MX360640B/en active IP Right Grant
- 2011-02-28 CA CA2787673A patent/CA2787673A1/en not_active Abandoned
- 2011-02-28 ES ES11751125.3T patent/ES2557407T3/en active Active
- 2011-02-28 EP EP11751125.3A patent/EP2542155B1/en not_active Not-in-force
-
2012
- 2012-07-18 ZA ZA2012/05377A patent/ZA201205377B/en unknown
- 2012-07-19 IL IL221035A patent/IL221035A0/en not_active IP Right Cessation
-
2013
- 2013-05-30 HK HK13106393.5A patent/HK1179143A1/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002092127A1 (en) | 2001-05-11 | 2002-11-21 | Board Of Regents, The University Of Texas System | Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26 |
WO2008018642A2 (en) | 2006-08-10 | 2008-02-14 | Oncotherapy Science, Inc. | Genes and polypeptides relating to breast cancers |
Non-Patent Citations (4)
Title |
---|
ASAGA, S.; UEDA, M.; JINNO, H.; KIKUCHI, K.; ITANO, O.; IKEDA, T.; KITAJIMA, M., ANTICANCER RES, vol. 26, 2006, pages 35 - 42 |
GRAY, L.S.; PEREZ-REYES, E.; GOMORA, J.C.; HAVERSTICK, D.M.; SHATTOCK, M.; MCLATCHIE, L.; HARPER, J.; BROOKS, G.; HEADY, .; MACDON, CELL CALCIUM, vol. 36, 2004, pages 489 - 497 |
HONG FRANK D ET AL., CARCINOGENEIS, vol. 20, no. 7, July 1999 (1999-07-01), pages 1161 - 1168 |
See also references of EP2542155A4 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9427429B2 (en) | 2010-03-01 | 2016-08-30 | Tau Therapeutics Llc | Cancer diagnosis and imaging |
US11130750B2 (en) | 2017-02-15 | 2021-09-28 | Cavion, Inc. | Calcium channel inhibitors |
Also Published As
Publication number | Publication date |
---|---|
MX2012010119A (en) | 2012-09-12 |
EP2542155A4 (en) | 2013-07-17 |
EP2542155A2 (en) | 2013-01-09 |
KR20130014506A (en) | 2013-02-07 |
EP2542155B1 (en) | 2015-11-04 |
WO2011109262A3 (en) | 2011-11-17 |
JP6017964B2 (en) | 2016-11-02 |
AU2011223883A1 (en) | 2012-09-13 |
AU2011223883B2 (en) | 2015-10-08 |
KR101821343B1 (en) | 2018-01-23 |
US20120321561A1 (en) | 2012-12-20 |
CN102781316B (en) | 2016-07-06 |
SG183114A1 (en) | 2012-09-27 |
ES2557407T3 (en) | 2016-01-25 |
JP2013521287A (en) | 2013-06-10 |
IL221035A0 (en) | 2012-09-24 |
US9427429B2 (en) | 2016-08-30 |
ZA201205377B (en) | 2013-09-25 |
HK1179143A1 (en) | 2013-09-27 |
MX360640B (en) | 2018-11-09 |
CA2787673A1 (en) | 2011-09-09 |
SG10201501496TA (en) | 2015-04-29 |
CN102781316A (en) | 2012-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9427429B2 (en) | Cancer diagnosis and imaging | |
McDougall et al. | Thyroid stunning: fact or fiction? | |
CN108430520A (en) | Long-acting gadolinium base cancer target imaging and therapeutic agent | |
Vibholm et al. | Activation of NMDA receptor ion channels by deep brain stimulation in the pig visualised with [18F] GE-179 PET | |
KR20210003135A (en) | Cancer treatment method | |
CN101678128A (en) | Nuclear magnetic resonance | |
KR20210095620A (en) | How to treat cancer | |
Chang et al. | Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma | |
US8633165B2 (en) | Neuroprotective effects of 2DG in traumatic brain injury | |
KR20230137877A (en) | Radiolabeled liposomes and methods of using the same | |
KR102369838B1 (en) | A Contrast Agent Composition for Detecting Lesional Margin of Astrocytosis-Related Disease Comprising Quinoline Derivatives as Active Ingredients | |
Adams et al. | Radioimmunotherapy of human lymphoma in athymic, nude mice as monitored by 31P nuclear magnetic resonance | |
KR102369854B1 (en) | A Contrast Agent Composition for Detecting Lesional Margin of Astrocytosis-Related Disease Comprising C11-Acetate as an Active Ingredient | |
Rahman Kawakibi et al. | PDCT-12. Clinical efficacy of onc201 in thalamic H3 K27M-mutant glioma | |
Zhao et al. | Intracranial 131I-chTNT brachytherapy in patients with deep-seated glioma: a single-center experience with 10-year follow-up from china | |
RU2737996C1 (en) | Method for evaluating neoadjuvant systemic therapy of breast cancer with her2/neu overexpression | |
AU2006316781B2 (en) | Therapy of malignant neoplasias | |
KR20210128125A (en) | A Contrast Agent Composition for Detecting Lesional Margin of Dementia Caused by Degenerative Brain Disease Comprising Quinoline Derivatives as Active Ingredients | |
Sabr et al. | STUDY THE TREATMENT PROCEDURE PROSTATE CANCER AND NEUROENDOCRINE TUMOR (NET) USING RADIOACTIVE MATERIAL LU-177 | |
KR20240116780A (en) | Radiopharmaceutical treatment methods and uses | |
Botushanova et al. | Parathyroid Scintigraphy | |
KR20210128127A (en) | A Contrast Agent Composition for Detecting Lesional Margin of Dementia Caused by Degenerative Brain Disease Comprising C11-Acetate as an Active Ingredient | |
CA3234495A1 (en) | Combination therapy of radionuclide complex | |
Soria-P | Dr. Stone Biochem-2 May 22, 2018 Reduction of Beta Amyloid and Reversal of Alzheimer's Disease | |
Reynolds et al. | Lucia Martiniova1, 7*, Shiromi M Perera1*, Frederieke M Brouwers1, Salvatore Alesci2, Mones Abu-Asab3, Amanda F Marvelle, Dale O Kiesewetter4, David Thomasson5, John C Morris6, Richard Kvetnansky7, Arthur S Tischler8 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180011495.2 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2787673 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 221035 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6477/DELNP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011223883 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011751125 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13581390 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 20127022975 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2012/010119 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012556123 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2011223883 Country of ref document: AU Date of ref document: 20110228 Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11751125 Country of ref document: EP Kind code of ref document: A2 |